Non-nucleoside reverse-transcriptase inhibitors (NNRTIs) are the third class of antiretroviral drugs that were developed. NNRTI resistance. edit. NNRTIs
by Y Wang 2024 Cited by 95Expert opinion: Since the first NNRTI, nevirapine, was approved in 2024, antiviral drug discovery led to the approval of seven NNRTIs, including nevirapine
NNRTI-higher than the NNRTI-low group. Children who either had not been treated with antiretroviral drugs or had received antiretroviral drugs
by MI Danjuma 2024 Cited by 3(NNRTI). This class of drugs There is the potential for significant drug interactions when NNRTIs are coadministered with other drugs
The specificity of the NNRTIs for HIV-1 is considered the hallmark of the NNRTI drug class. Five drugs in the class of NNRTIs have been approved by regulatory
Non-nucleoside reverse-transcriptase inhibitors (NNRTIs) are antiretroviral drugs used in the treatment of human immunodeficiency virus ().NNRTIs inhibit reverse transcriptase (RT), an enzyme that controls the replication of the genetic material of HIV.
by JSA Stringer 2024 Cited by 70(NNRTI) drugs. This drug resistance largely fades over time. We (NNRTI) class of antiretroviral drugs [11],[12]. Population
Efficacy for the NNRTI drug class is reduced by mutations within or near the NNRTI binding pocket (NNIBP). Drug resistance poses a considerable challenge in anti-HIV-1 drug discovery. Among the approved NNRTIs drugs, EFV, RPV, and DOR are approved in combination with NRTIs or integrase strand transfer inhibitor (INSTI) to overcome viral resistance.
by D Frentz Cited by 59drug resistance mutations to NRTI, NNRTI, or PI drug class drugs. For the NNRTI TDRM, the prevalence was 2.0% in. 2024 and increased to
Comments